DC Bead Lumi
- Radiopaque drug-eluting bead
- Visible under imaging during and after embolization
- ELasting confirmation of bead location
- Drug-loadable with doxorubicin or irinotecan
- New level of control for transarterial chemoembolization (TACE) procedures
DC Bead Lumi are intended to be used for the embolization of hypervascular tumors and arteriovenous malformations. They are precisely calibrated, radiopaque embolic drug-eluting beads developed using the same core chemistry as the clinically proven DC Bead. DC Bead Lumi contains a covalently bound radiopaque moiety to offer inherent, lasting radiopacity. The beads are visible in various imaging modes (CT, cone-beam CT, and fluoroscopy) during the procedure and at follow-up.
“The ability to see bead location during TACE procedures is a key step in enhancing the quality and potentially minimizing complications of the procedure, and can help improve treatment outcomes compared with current techniques,” said Tobias Jakobs, MD, of the Hospital of the Order of St. John of God, Munich, Germany. “More importantly, the lasting radiopacity of DC Bead Lumi means I can show patients that treatment has been placed exactly where it’s needed.”
The DC Bead Lumi has received Class III CE Mark certification in Europe, and is also approved in Canada.